Clinical trials, including Anti-VEGF Antibody for the Treatment of Predominantly Classic Choroidal Neovascularization in Age-Related Macular Degeneration (ANCHOR) [66], Minimally Classic/Occult Trial of the Anti-VEGF Antibody Ranibizumab in the Treatment of Neovascular Age-Related Macular Degeneration MARINA [66], and the OAKS [67] and DERBY [67] trials, have demonstrated that these therapies effectively preserve and improve central vision. Here, VEGFA is linked to age-related macular degeneration.